Correlative analysis from a phase I clinical trial of intrapleural administration of oncolytic vaccinia virus (Olvi-vec) in patients with malignant pleural mesothelioma
Abstract
The attenuated, genetically engineered vaccinia virus has been shown to be a promising oncolytic virus for the treatment of patients with solid tumors, through both direct cytotoxic and immune-activating effects. Whereas systemically administered oncolytic viruses can be neutralized by pre-existing antibodies, locoregionally administered viruses can infect tumor cells and generate immune responses. We conducted a phase I clinical trial to investigate the safety, feasibility and immune activating effects of intrapleural administration of oncolytic vaccinia virus (NCT01766739).
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Feb 16, 2023
- Source ID
- 10.3389/fimmu.2023.1112960
Entities
People
- Andre L. Moreira
- Erin Mcgee
- Jasmeen Saini
- Jennie K. Choe
- Marjorie Zauderer
- Navin K. Chintala
- Prasad S Adusumilli
- Rebecca Bellis
- Srijita Banerjee
- Valerie W. Rusch
Organizations
- National Institutes of Health
- United States Department of Defense